Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852769 | 1.00 | CA12 (0.44) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL2857462 | 0.90 | CA12 (0.55) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL2857461 | 0.90 | CA12 (0.55) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL1827972 | 0.89 | CA12 (0.43) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL1827970 | 0.89 | CA12 (0.43) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL2863719 | 0.88 | CA12 (0.45) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL2863723 | 0.88 | CA12 (0.45) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL2855588 | 0.87 | ITGA4 (0.57) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL2855590 | 0.87 | ITGA4 (0.57) | CA12CA7CA9CA14ITGA4 | |
| SCHEMBL1826435 | 0.87 | KDM4E (0.46) | CA12CA7CA9CA14HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346971-B1 | Production method for biarylalanine | SUMITOMO CHEMICAL CO (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | CA12 1913/4885CA7 801/4885CA9 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.